Ivonescimab Beats Keytruda on Overall Survival in Phase III Lung Cancer Trial
SMMT sits 47% above its 52-week low of $12.07.
Summary
Updated HARMONi-2 data show ivonescimab monotherapy cut the risk of death by 27% versus pembrolizumab in PD-L1-positive advanced NSCLC (HR 0.73, p=0.009), with median OS of 30.8 vs 22.6 months. This is the first OS readout from the China-based trial and strengthens the case for the drug's global potential ahead of the FDA decision on the HARMONi BLA in November. Subgroup benefits were consistent, including a strong HR of 0.58 in PD-L1-high patients. Safety remains manageable with no new signals. The data will be presented at WCLC on September 15, and the ongoing global HARMONi-7 trial will test the same comparison in a Western population.
At the time of this announcement, SMMT was trading at $17.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14B. The 52-week trading range was $12.07 to $29.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.